TITLE

Other News To Note

PUB. DATE
March 2013
SOURCE
BioWorld Today;3/27/2013, Vol. 24 Issue 58, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on developments in biotechnology and pharmaceuticals. Acceleron Pharma Inc. said that the U.S. Food and Drug Administration (FDA) has granted orphan designation for ACE-536 in treating beta-thalassemia and myelodysplastic syndromes. BioDelivery Sciences International Inc. (BDSI) has entered a global licensing agreement with Arcion Therapeutics Inc. to develop and commercialize topical clonidine gel for treating diabetic neuropathy.
ACCESSION #
86442011

 

Related Articles

  • BDSI, Meda Partner On $90M+ Licensing Deal For Opioid Disc. Young, Donna // BioWorld Today;9/6/2007, Vol. 18 Issue 173, p1 

    The article reports that BioDelivery Sciences International Inc. (BDSI) is set to receive an up-front payment from Swedish specialty pharmaceutical firm Meda AB in 2007 under a licensing agreement for BEMA Fentanyl, a dissolvable opioid disc product. The agreement will cover the U.S., Canadian...

  • Regulatory Update.  // PharmaWatch: CNS;Nov2010, Vol. 9 Issue 11, p15 

    The article reports on the fast track designation granted by the U.S. Food and Drug Administration (FDA) to ARC-4558 from Arcion Therapeutics Inc. for the treatment of pain related with painful diabetic neuropathy (PDN).

  • Other News To Note.  // BioWorld International;3/28/2012, Vol. 17 Issue 13, p9 

    The article offers news briefs related to biotechnology. A licensing and development agreement was signed by Kuros Biosurgery AG and Synthes GmbH for the commercialization of the former's synthetic matrix technology. The 5.7-billion U.S. dollar offer for the acquisition of tools firm Illumina...

  • ONSOLIS to Benefit from Approval of Class-Wide REMS.  // Biotech Business;Feb2012, Vol. 25 Issue 2, p5 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) for BioDelivery Sciences International, Inc. for its Risk Evaluation Mitigation Strategy (REMS) covering all transmucosal fentanyl products. The program, to be called the Transmucosal Immediate Release Fentanyl...

  • OTHER NEWS TO NOTE.  // BioWorld Today;9/17/2007, Vol. 18 Issue 180, p2 

    The article offers news briefs on the U.S. pharmaceutical industry. An initial $30 million nonrefundable milestone payment has been received by BioDelivery Sciences International Inc. from Meda AB. In collaboration with the U.S. Food and Drug Administration (FDA), Cephalon Inc. has sent letters...

  • BDSI's Cancer Pain Film Onsolis Wins FDA OK.  // Bioworld Week;7/20/2009, Vol. 17 Issue 29, p5 

    The article reports that BioDelivery Sciences International Inc.'s drug Onsolis got the approval of the U.S. Food & Drug Administration (FDA) on July 16, 2009. FDA approved Onsolis, its soluble film version of fentanyl in breakthrough cancer pain, guaranteeing the company a sum of 27 million...

  • BDSI anti-nausea drug moves closer to approval.  // PharmaWatch: Biotechnology;Sep2005, Vol. 4 Issue 9, p11 

    The article reports that BioDelivery Sciences International Inc. has announced that it has received written notification from the U.S. Food and Drug Administration that its new drug application for Emezine, an orally administered anti nausea and vomiting drug, has been accepted for review....

  • Financings roundup.  // Medical Device Daily;7/23/2009, Vol. 13 Issue 140, p2 

    The article reports that BioDelivery Sciences International (BDSI) has received $26.7 million in payments from its commercial partner Meda. This receipt was made through the approval of the U.S. Food and Drug Administration (FDA) of BDSI's cancer pain product Onsolis and satisfactory preparation...

  • Drug for Opioid Dependence Expected to Debut in Fall.  // Chain Drug Review;7/72014, Vol. 36 Issue 11, p57 

    The article reports that BioDelivery Sciences International Inc. has received approval of the New Drug Application for Bunavail buccal film (CIII) from the Food and Drug Administration.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics